Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
JPY 309.0
(6.92%)
JPY 309.0
(6.92%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.73 Billion JPY | -10.65% |
| 2022 | 8.66 Billion JPY | 3.31% |
| 2021 | 8.38 Billion JPY | -5.75% |
| 2020 | 8.89 Billion JPY | -18.53% |
| 2019 | 10.91 Billion JPY | 1.64% |
| 2018 | 10.74 Billion JPY | -1.46% |
| 2017 | 10.9 Billion JPY | 0.63% |
| 2016 | 10.83 Billion JPY | -3.23% |
| 2015 | 11.19 Billion JPY | 5.47% |
| 2014 | 10.61 Billion JPY | 2.9% |
| 2013 | 10.31 Billion JPY | 3.93% |
| 2012 | 9.92 Billion JPY | 5.24% |
| 2011 | 9.42 Billion JPY | -2.5% |
| 2010 | 9.67 Billion JPY | -1.1% |
| 2009 | 9.77 Billion JPY | -2.99% |
| 2008 | 10.08 Billion JPY | -0.98% |
| 2007 | 10.18 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.88 Billion JPY | -21.23% |
| 2023 Q1 | 1.86 Billion JPY | -22.24% |
| 2023 FY | 7.73 Billion JPY | -10.65% |
| 2023 Q4 | 2.39 Billion JPY | 21.56% |
| 2023 Q3 | 1.96 Billion JPY | 11.94% |
| 2023 Q2 | 1.75 Billion JPY | -5.5% |
| 2022 Q3 | 2.24 Billion JPY | 12.63% |
| 2022 FY | 8.66 Billion JPY | 3.31% |
| 2022 Q4 | 2.39 Billion JPY | 6.41% |
| 2022 Q2 | 1.99 Billion JPY | -1.34% |
| 2022 Q1 | 2.02 Billion JPY | -4.41% |
| 2021 Q3 | 2.25 Billion JPY | 10.66% |
| 2021 FY | 8.38 Billion JPY | -5.75% |
| 2021 Q4 | 2.11 Billion JPY | -6.31% |
| 2021 Q1 | 1.96 Billion JPY | -11.46% |
| 2021 Q2 | 2.04 Billion JPY | 3.88% |
| 2020 Q3 | 2.39 Billion JPY | 11.27% |
| 2020 Q2 | 2.15 Billion JPY | 0.96% |
| 2020 Q1 | 2.13 Billion JPY | -12.36% |
| 2020 Q4 | 2.21 Billion JPY | -7.26% |
| 2020 FY | 8.89 Billion JPY | -18.53% |
| 2019 Q1 | 2.73 Billion JPY | 3.08% |
| 2019 FY | 10.91 Billion JPY | 1.64% |
| 2019 Q2 | 2.64 Billion JPY | -3.47% |
| 2019 Q3 | 3.1 Billion JPY | 17.51% |
| 2019 Q4 | 2.43 Billion JPY | -21.73% |
| 2018 Q4 | 2.65 Billion JPY | -7.1% |
| 2018 FY | 10.74 Billion JPY | -1.46% |
| 2018 Q1 | 2.69 Billion JPY | 7.24% |
| 2018 Q3 | 2.85 Billion JPY | 13.05% |
| 2018 Q2 | 2.52 Billion JPY | -6.22% |
| 2017 Q4 | 2.51 Billion JPY | -15.12% |
| 2017 Q2 | 2.7 Billion JPY | -0.25% |
| 2017 FY | 10.9 Billion JPY | 0.63% |
| 2017 Q1 | 2.71 Billion JPY | 8.8% |
| 2017 Q3 | 2.96 Billion JPY | 9.42% |
| 2016 FY | 10.83 Billion JPY | -3.23% |
| 2016 Q1 | 2.88 Billion JPY | 9.93% |
| 2016 Q3 | 2.84 Billion JPY | 9.49% |
| 2016 Q2 | 2.6 Billion JPY | -9.81% |
| 2016 Q4 | 2.49 Billion JPY | -12.43% |
| 2015 Q3 | 3.13 Billion JPY | 18.73% |
| 2015 Q4 | 2.62 Billion JPY | -16.39% |
| 2015 FY | 11.19 Billion JPY | 5.47% |
| 2015 Q1 | 2.78 Billion JPY | 8.73% |
| 2015 Q2 | 2.64 Billion JPY | -5.09% |
| 2014 Q4 | 2.56 Billion JPY | -9.86% |
| 2014 FY | 10.61 Billion JPY | 2.9% |
| 2014 Q3 | 2.84 Billion JPY | 8.14% |
| 2014 Q2 | 2.62 Billion JPY | 1.87% |
| 2014 Q1 | 2.58 Billion JPY | 2.0% |
| 2013 Q3 | 2.85 Billion JPY | 16.83% |
| 2013 Q4 | 2.52 Billion JPY | -11.33% |
| 2013 FY | 10.31 Billion JPY | 3.93% |
| 2013 Q1 | 2.48 Billion JPY | -5.3% |
| 2013 Q2 | 2.44 Billion JPY | -1.92% |
| 2012 Q3 | 2.57 Billion JPY | 8.47% |
| 2012 Q4 | 2.62 Billion JPY | 2.09% |
| 2012 FY | 9.92 Billion JPY | 5.24% |
| 2012 Q1 | 2.34 Billion JPY | 4.47% |
| 2012 Q2 | 2.37 Billion JPY | 1.21% |
| 2011 FY | 9.42 Billion JPY | -2.5% |
| 2011 Q1 | 2.39 Billion JPY | -4.65% |
| 2011 Q2 | 2.34 Billion JPY | -1.87% |
| 2011 Q3 | 2.44 Billion JPY | 4.3% |
| 2011 Q4 | 2.24 Billion JPY | -8.26% |
| 2010 FY | 9.67 Billion JPY | -1.1% |
| 2010 Q2 | 2.32 Billion JPY | 0.51% |
| 2010 Q1 | 2.31 Billion JPY | -0.21% |
| 2010 Q3 | 2.52 Billion JPY | 8.66% |
| 2010 Q4 | 2.5 Billion JPY | -0.73% |
| 2009 Q4 | 2.31 Billion JPY | -10.06% |
| 2009 Q1 | 2.27 Billion JPY | -4.12% |
| 2009 FY | 9.77 Billion JPY | -2.99% |
| 2009 Q2 | 2.61 Billion JPY | 14.96% |
| 2009 Q3 | 2.57 Billion JPY | -1.33% |
| 2008 Q4 | 2.36 Billion JPY | -10.45% |
| 2008 Q3 | 2.64 Billion JPY | 4.57% |
| 2008 Q2 | 2.53 Billion JPY | 0.0% |
| 2008 FY | 10.08 Billion JPY | -0.98% |
| 2007 FY | 10.18 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 87.548% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.819% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 97.54% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 98.221% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 94.78% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 89.259% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 98.957% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 37.624% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 94.539% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 92.479% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 86.033% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 74.833% |
| Tsumura & Co. | 150.84 Billion JPY | 94.87% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 89.761% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 85.837% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 96.605% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 81.075% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 89.781% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 93.526% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -53.54% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 83.498% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -38.441% |
| MedRx Co., Ltd | 26 Million JPY | -29663.177% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 29.585% |
| Solasia Pharma K.K. | 617 Million JPY | -1154.202% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 87.686% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 95.625% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -12562.695% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.476% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 65.039% |